Jill Sanchez - Vaccinex Interim Controller
Executive
Jill Sanchez is Interim Controller of Vaccinex
| Age | 52 |
| Phone | 585 271 2700 |
| Web | https://www.vaccinex.com |
Jill Sanchez Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jill Sanchez against Vaccinex stock is an integral part of due diligence when investing in Vaccinex. Jill Sanchez insider activity provides valuable insight into whether Vaccinex is net buyers or sellers over its current business cycle. Note, Vaccinex insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vaccinex'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jill Sanchez over three months ago Disposition of tradable shares by Jill Sanchez of Vaccinex at 615.3 subject to Rule 16b-3 | ||
Jill Sanchez over six months ago Disposition of tradable shares by Jill Sanchez of Vaccinex at 615.3 subject to Rule 16b-3 | ||
Jill Sanchez over six months ago Disposition of tradable shares by Jill Sanchez of Vaccinex at 1045.8 subject to Rule 16b-3 |
Vaccinex Management Efficiency
The company has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities.Vaccinex currently holds 247 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Vaccinex has a current ratio of 8.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vaccinex's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Varney | Erasca Inc | 67 | |
| Chandra MS | Erasca Inc | 54 | |
| Li Yang | Surrozen | 56 | |
| Paul Little | Eledon Pharmaceuticals | 60 | |
| John Niles | GeoVax Labs | N/A | |
| John Sharkey | GeoVax Labs | 69 | |
| MS CPA | Erasca Inc | 58 | |
| Esq JD | Erasca Inc | 52 | |
| Mary Grendell | Protara Therapeutics | N/A | |
| Justine OMalley | Protara Therapeutics | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| FACS FACS | Eledon Pharmaceuticals | N/A | |
| Leesa Gentry | RenovoRx | 55 | |
| Daniel George | Anebulo Pharmaceuticals | 55 | |
| Robert Shoemaker | Erasca Inc | 44 | |
| Jathin MD | Protara Therapeutics | 36 | |
| Patrick MBA | Protara Therapeutics | 57 | |
| Thomas OBrien | GeoVax Labs | N/A | |
| JD Esq | Erasca Inc | 53 | |
| Esther Jhun | Surrozen | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
Management Performance
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 |
Vaccinex Leadership Team
Elected by the shareholders, the Vaccinex's board of directors comprises two types of representatives: Vaccinex inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaccinex. The board's role is to monitor Vaccinex's management team and ensure that shareholders' interests are well served. Vaccinex's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaccinex's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jill CPA, Chief Officer | ||
| Jill Sanchez, Interim Controller | ||
| MBA CFA, Chief Officer | ||
| Ernest Smith, Senior Officer | ||
| Maurice Zauderer, CEO, CoFounder | ||
| Elizabeth Evans, COO Medicine | ||
| John Leonard, Senior Development |
Vaccinex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaccinex a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 | ||||
| Current Valuation | 1.59 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 11.50 % | ||||
| Shares Owned By Institutions | 51.30 % | ||||
| Number Of Shares Shorted | 62.11 K | ||||
| Price To Book | 7.34 X | ||||
| Price To Sales | 4.34 X | ||||
| Revenue | 570 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Vaccinex Stock
If you are still planning to invest in Vaccinex check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccinex's history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |